1
|
Espitia-Corredor JA, Boza P, Espinoza-Pérez C, Lillo JM, Rimassa-Taré C, Machuca V, Osorio-Sandoval JM, Vivar R, Bolivar S, Pardo-Jiménez V, Sánchez-Ferrer CF, Peiró C, Díaz-Araya G. Angiotensin II Triggers NLRP3 Inflammasome Activation by a Ca 2+ Signaling-Dependent Pathway in Rat Cardiac Fibroblast Ang-II by a Ca 2+-Dependent Mechanism Triggers NLRP3 Inflammasome in CF. Inflammation 2022; 45:2498-2512. [PMID: 35867264 DOI: 10.1007/s10753-022-01707-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Revised: 05/13/2022] [Accepted: 06/09/2022] [Indexed: 11/05/2022]
Abstract
Angiotensin II (Ang-II) is a widely studied hypertensive, profibrotic, and pro-inflammatory peptide. In the heart, cardiac fibroblasts (CF) express type 1 angiotensin II receptors (AT1R), Toll-like receptor-4 (TLR4), and the NLRP3 inflammasome complex, which play important roles in pro-inflammatory processes. When activated, the NLRP3 inflammasome triggers proteolytic cleavage of pro-IL-1, resulting in its activation. However, in CF the mechanism by which Ang-II assembles and activates the NLRP3 inflammasome remains not fully known. To elucidate this important point, we stimulated TLR4 receptors in CF and evaluated the signaling pathways by which Ang-II triggers the assembly and activity. In cultured rat CF, pro-IL-1β levels, NLRP3, ASC, and caspase-1 expression levels were determined by Western blot. NLRP3 inflammasome complex assembly was analyzed by immunocytochemistry, whereas by ELISA, we analyzed NLRP3 inflammasome activity and [Formula: see text] release. In CF, Ang-II triggered NLRP3 inflammasome assembly and caspase-1 activity; and in LPS-pretreated CF, Ang-II also triggered [Formula: see text] secretion. These effects were blocked by losartan (AT1R antagonist), U73221 (PLC inhibitor), 2-APB (IP3R antagonist), and BAPTA-AM (Ca2+ chelator) indicating that the AT1R/PLC/IP3R/Ca2+ pathway is involved. Finally, bafilomycin A1 prevented Ang-II-induced [Formula: see text] secretion, indicating that a non-classical protein secretion mechanism is involved. These findings suggest that in CF, Ang-II by a Ca2+-dependent mechanism triggers NLRP3 inflammasome assembly and activation leading to [Formula: see text] secretion through a non-conventional protein secretion mechanism.
Collapse
Affiliation(s)
- Jenaro Antonio Espitia-Corredor
- Laboratory of Molecular Pharmacology, Faculty of Chemical and Pharmaceutical Sciences, Department of Pharmacological & Toxicological Chemistry, University of Chile, Santiago, Chile.,Faculty of Medicine, Department of Pharmacology, Universidad Autónoma de Madrid, Madrid, Spain.,PhD Programme in Pharmacology and Physiology, Doctoral School, Universidad Autónoma de Madrid, Madrid, Spain.,Faculty of Chemical and Pharmaceutical Sciences, Advanced Center of Chronic Diseases (ACCDiS), University of Chile, Santiago, Chile
| | - Pía Boza
- Laboratory of Molecular Pharmacology, Faculty of Chemical and Pharmaceutical Sciences, Department of Pharmacological & Toxicological Chemistry, University of Chile, Santiago, Chile
| | - Claudio Espinoza-Pérez
- Laboratory of Molecular Pharmacology, Faculty of Chemical and Pharmaceutical Sciences, Department of Pharmacological & Toxicological Chemistry, University of Chile, Santiago, Chile
| | - José Miguel Lillo
- Laboratory of Molecular Pharmacology, Faculty of Chemical and Pharmaceutical Sciences, Department of Pharmacological & Toxicological Chemistry, University of Chile, Santiago, Chile
| | - Constanza Rimassa-Taré
- Laboratory of Molecular Pharmacology, Faculty of Chemical and Pharmaceutical Sciences, Department of Pharmacological & Toxicological Chemistry, University of Chile, Santiago, Chile
| | - Víctor Machuca
- Laboratory of Molecular Pharmacology, Faculty of Chemical and Pharmaceutical Sciences, Department of Pharmacological & Toxicological Chemistry, University of Chile, Santiago, Chile
| | - José Miguel Osorio-Sandoval
- Laboratory of Molecular Pharmacology, Faculty of Chemical and Pharmaceutical Sciences, Department of Pharmacological & Toxicological Chemistry, University of Chile, Santiago, Chile
| | - Raúl Vivar
- Molecular and Clinical Pharmacology Program, Faculty of Medicine, Institute of Biomedical Sciences (ICBM), University of Chile, Santiago, Chile
| | - Samir Bolivar
- Faculty of Chemistry and Pharmacy, Universidad del Atlántico, Barranquilla, Colombia
| | - Viviana Pardo-Jiménez
- Laboratory of Molecular Pharmacology, Faculty of Chemical and Pharmaceutical Sciences, Department of Pharmacological & Toxicological Chemistry, University of Chile, Santiago, Chile
| | - Carlos Félix Sánchez-Ferrer
- Faculty of Medicine, Department of Pharmacology, Universidad Autónoma de Madrid, Madrid, Spain.,Instituto de Investigaciones Sanitarias (IdiPAZ), Madrid, Spain
| | - Concepción Peiró
- Faculty of Medicine, Department of Pharmacology, Universidad Autónoma de Madrid, Madrid, Spain.,Instituto de Investigaciones Sanitarias (IdiPAZ), Madrid, Spain
| | - Guillermo Díaz-Araya
- Laboratory of Molecular Pharmacology, Faculty of Chemical and Pharmaceutical Sciences, Department of Pharmacological & Toxicological Chemistry, University of Chile, Santiago, Chile. .,Faculty of Chemical and Pharmaceutical Sciences, Advanced Center of Chronic Diseases (ACCDiS), University of Chile, Santiago, Chile.
| |
Collapse
|